propafenone has been researched along with Cardiomyopathy, Hypertrophic in 5 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Cardiomyopathy, Hypertrophic: A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone has a more favourable therapeutic profile than flecainide and propafenone in these patients, having less tendency to worsen heart failure." | 2.67 | A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.). ( , 1992) |
| "None of the medical treatments of hypertrophic cardiomyopathy is perfect." | 1.27 | [Hemodynamic effects on intravenous propafenone in hypertrophic myocardiopathy]. ( Benoit, P; Bourmayan, C; Cristofini, P; Desnos, M; Fernandez, F; Funck, F; Gay, J; Wajman, A, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Granja, PE | 1 |
| Sandín-Fuentes, M | 1 |
| García-Morán, E | 1 |
| Sevilla, T | 1 |
| Rubio, J | 1 |
| Nawrocka, I | 1 |
| Kaczyńska, A | 1 |
| Abramczyk, P | 1 |
| Campbell, RW | 1 |
| Funck, F | 1 |
| Bourmayan, C | 1 |
| Cristofini, P | 1 |
| Desnos, M | 1 |
| Fernandez, F | 1 |
| Benoit, P | 1 |
| Wajman, A | 1 |
| Gay, J | 1 |
1 review available for propafenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Is drug treatment of tachyarrhythmias a science or a lottery?
Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Flecainide; Humans; Propafenone; Tachycardia | 1990 |
1 trial available for propafenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
A multicentre, randomized trial on the benefit/risk profile of amiodarone, flecainide and propafenone in patients with cardiac disease and complex ventricular arrhythmias. Antiarrhythmic Drug Evaluation Group (A.D.E.G.).
Topics: Amiodarone; Cardiomyopathy, Dilated; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; | 1992 |
3 other studies available for propafenone and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Worsening Conduction Delay in Hypertrophic Cardiomyopathy: What Drug Is Responsible?
Topics: Action Potentials; Anti-Arrhythmia Agents; Atrioventricular Block; Cardiomyopathy, Hypertrophic; Ele | 2017 |
Electric cardioversion of atrial fibrillation resulting in pulmonary oedema in patient with apical hypertrophic cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Diuretics; Electric Count | 2015 |
[Hemodynamic effects on intravenous propafenone in hypertrophic myocardiopathy].
Topics: Adolescent; Adult; Aged; Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Diastole; Female; He | 1988 |